EPA

Major Depressive Disorder

Massachusetts General HospitalSmall moleculePhase 2/3Dormant

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 89/ 100

Competitive context

198 Active assets in the Major Depressive Disorder cohort.

Asset / Sponsor	Phase	Rating
Selegiline Corium Innovations, Inc.	Phase 4	BBB
Risperidone Johns Hopkins University	Phase 4	BBB
EDIVOXETINE Eli Lilly and Company	Phase 3	BBB
(1S,2R)-MILNACIPRAN Allergan	Phase 4	BBB
Brexpiprazole Nova Scotia Health Authority	Phase 4	BBB

View all 50 →

Same molecule, other indications

EPA is also rated in:

drug-induced dyskinesiaDormant

BB

Indicative · Phase 4

68 / 100

classic familial adenomatous polyposisDormant

BB

Indicative · Phase 3

66 / 100

schizophreniaDormant

B

Indicative · Phase 4

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.